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Public sector healthcare services are both large users and innovators of health tech-
nologies. In the UK’s National Health Service (NHS) initiatives have been developed
to manage the process of technological innovation more eﬀectively. This has two main
aims, to maximize potential commercial returns from innovations developed within the
NHS; and to improve levels of patient care through appropriate diﬀusion of innovations.
The initiatives have been devised using approaches and processes already used in other
public sector organizations, in particular, universities. Central to the approach taken by
many universities is the setting up of a university technology transfer oﬃce (UTTO)
to provide innovation management services. This paper assesses the extent to which the
UTTO-based approach to technology transfer matches the needs of the NHS. Several sig-
niﬁcant factors are identiﬁed that suggest that the two sectors merit diﬀerent approaches
to innovation management. An agenda for further research into health service innovation
management processes is suggested that emphasises issues including: the relative roles of
formal and informal innovation processes; contingent variables aﬀecting design of inno-
vation processes; limitations of technology-push approaches to managing practice-based
innovation; and cultural ﬁt of innovation management models.
Keywords: Technological innovation; technology transfer; innovation hub; Nation Health
Service.
1. Introduction
One of the results of the drive to modernize the UK’s National Health Service (NHS)
has been eﬀorts to support innovation, particularly in relation to improvements in
patient services and care and the development of hard technologies such as medi-
cal devices [UK Government (2000)]. These innovations are often rooted in formal
research projects but can also result from ideas, inventions and process changes
produced by NHS employees in the course of their work.
From its position as the largest employer in the UK, the NHS recognizes the
potential for innovation activities is massive and as a consequence has started to
invest in mechanisms to manage innovation and facilitate technology transfer. The
way it has chosen to do this is to set up a number of innovation hubs, some of
which are an integral part of the NHS itself [NHS Innovations (2004)]. These hubs
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have drawn staﬀ from within the NHS, from private technology transfer companies
and from University Technology Transfer Oﬃces (UTTOs) and their structure and
operation are modeled on UTTOs. The role of the hubs however is primarily to
support technology transfer out of the NHS, based on a pipeline model of innovation
where IP is exploited through ﬁrst protection and commercialization. The main
measures of success used for the hubs are numbers of patents and licensing deals
brokered.
The role of universities within national innovation systems has been established
as vital to innovative activities [Nelson (1990)]. The role is however not purely as a
source of innovation but as a member of a network of relationships spanning gov-
ernment and industry [Etzkowitz and Leydesdorﬀ (2000)]. UTTOs have existed in
the US and the UK for several years and have played an important part in manag-
ing and capitalizing on intellectual property (IP) produced within universities. The
deﬁning purpose of the UTTO can be characterized as to “. . . facilitate technologi-
cal diﬀusion through the licensing to industry of inventions or intellectual property
resulting from university research” [Siegel et al. (2003)]. This emphasis on identify-
ing and commercialising new technologies can be viewed as underpinning a purely
“technology push” model of innovation [Howells (1997)]. Even within a university
context this has not been seen by all writers as always beneﬁcial [Colyvas et al.
(2002)].
The author of this paper believes that the perceived success of the UTTO model
of innovation in commercializing university research has resulted in its uncritical
application to the NHS. Unfortunately, the purpose and structure of the NHS
requires application of a more sophisticated model of innovation, to ensure that
maximum value is gained from the inventions created by its employees. This paper
questions the extent to which it is appropriate to model the operation of NHS inno-
vation hubs on the operation of UTTOs. It suggests that the organizational aims
and context of the NHS are suﬃciently unique to suggest that innovation processes
should be encouraged to operate very diﬀerently. After reviewing the background
to the current NHS initiatives the paper sets out a research agenda that supports
the development of a better understanding of the innovation management challenge
in the NHS.
2. History of Government Policy
Innovation in the NHS has now held the serious attention of the UK government
for over a decade. This is for three reasons. First, the potential commercial value of
innovations in the global healthcare market leading to additional income streams
for the NHS. Second, the potential oﬀered by innovations to transform the services
provided by the NHS and improve patient care. Finally, the sources of innovation in
the NHS are not just those engaged in formal research projects; many innovations
stem from everyday work situations.
In the 1990s, the UK government recognized that the inventions developed in
the UK’s public sector research establishments (PSRE) were often poorly com-
mercialized. In his report to the UK government, Minister for Science John Baker
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commented: “It is generally perceived in Government and in PSREs, . . . that the
Government sector taken as a whole is not as advanced in the knowledge transfer
arena as the best of the university sector or as the Government sector in the US”
[Baker (1999)]. This led to IP rights not being appropriately protected, limiting the
extent to which their full commercial value was achieved. To counter this PSREs
were encouraged to make the commercialization of IP a priority. This prompted
PSREs to setup technology transfer companies to provide speciﬁc support services.
These companies provide services such as: identifying important IP; legal advice on
protection of IP; and support in commercializing the IP through licensing or the
set up of spin-oﬀ companies.
It was not until the late 1990s that signiﬁcant attention was drawn to the per-
formance of innovation in the NHS. In 1994 the Culyer Report [Culyer (1994)] set
out a new strategy for R&D in the NHS. This recognized that much research in the
NHS was done outside of teaching hospitals. It recommended that all the money
spent by the NHS on R&D should be brought together into a single funding stream
with primary, secondary, and acute sectors all having equal access to R&D funding.
In addition, there was a new requirement for research to be eﬀectively managed in
order to achieve best value for money. This gave NHS trusts explicit funding for
R&D. While changing the basis on which NHS trusts were able to manage their
research, there was still little centralized guidance or control of how any resulting
intellectual property was protected or commercially exploited.
Teaching hospitals have traditionally had close partnerships with universities. In
these cases it was usually existing UTTOs that provided support for commercializ-
ing IP. However, for other inventions developed by NHS staﬀ there was no obvious
route or mechanism for commercializing IP. In some cases, individuals would pur-
sue the innovation through private agreements with external organizations. In other
cases, the innovation would either remain in use on a localized basis or would simply
be forgotten.
The Baker report [Baker (1999)] emphasized the potential for gaining economic
beneﬁts from public sector research establishments (PSRE). While the report made
general comments on UK PSREs, it had particular relevance to the NHS. Its main
recommendations were accepted by the UK government. This lead to the gov-
ernment’s response [Oﬃce of Science and Technology (2000)] focusing around the
need for PSREs to have: an explicit knowledge transfer mission; necessary ﬁnancial
freedom; control and ownership of IP; access to necessary skills and advice; per-
sonal incentives for staﬀ. As a direct result of the report several high level changes
occurred. In July 2000, changes were made to allow government scientists new incen-
tives and rewards for participating in the exploitation of inventions. The report also
triggered moves to reduce the risk-averse culture of PSREs. The National Audit
oﬃce published a statement “. . . conﬁrming that they will adopt an open-minded
and supportive approach to commercialization by PSREs, focusing on their com-
mitment to exploitation, the quality of their risk management, and the lessons that
can be learned for PSREs as a whole” [Oﬃce of Science and Technology (2000)].
This represented high level support for PSREs adopting a forward looking inno-
vative culture that recognised that a level of commercial risk was inherent in any
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innovative activity; in contrast to the existing “culture of risk avoidance”. This was
to be achieved by ensuring that audit methodologies would incorporate a “positive
approach to risk”. For the NHS in particular the Baker report was to change the
way NHS trusts were able to take ownership of IP and then exploit it.
Subsequent to the Baker report other initiatives were made that aimed to sup-
port innovation in the NHS. The development of the NHS innovation hubs was
outlined in a Department of Health framework and guidance paper [DoH (2002)].
In this, the hubs were given the role of “advisor” organizations, providing IP services
including: technology audits; training of NHS employees on IP issues; evaluating IP
and initiating additional R&D to produce evidence of clinical application; regis-
tering IP; commissioning production of prototypes; advising on and exploiting IP
through licensing or through the setting up of companies; collaborating with univer-
sities and other third parties in the exploitation of IP generated jointly with NHS
trusts.
The position of the UK government to innovation in the NHS, made clear in the
DoH paper, was that two distinct categories of innovation exist. The ﬁrst of these
are those that have some commercial value. For these types of innovation, there is
opportunity to commercialize the IP and develop products suitable for the global
healthcare market. These innovations include diagnostic and therapeutic devices.
These types of innovations were the focus of attempts to improve technology transfer
processes out of the NHS. The second category are innovations that have “. . . no
commercial value but the potential to improve health and to save expenditure by
the NHS” (p. 11). These are commonly service improvements. Service innovations
were seen predominantly as “best practices” to be diﬀused freely through the NHS.
The NHS Modernisation Agency, was established in 2001, as the preferred agency
to deal with service innovations. The implicit assumption embodied in this view of
innovation is that the innovation of hard technologies is a separate activity from
innovation of services. This is an oversimpliﬁcation as many innovations combine
hard and soft technologies. The true value of the innovation is based on synergy
gained from the synthesis of technologies. This binary view resulted in two separate
agencies becoming responsible for dealing with NHS innovations: NHS Innovations
for commercially viable innovation and the NHS Modernisation Agency for “best
practices”.
The Department of Health approach to NHS innovation was also heavily based
on a technology push based model of innovation. The proposed hubs were expected
to “search” the NHS for potentially valuable IP. This approach emphasized the
“. . . commercialization of a pipeline of innovations coming from the NHS. . . ” [HITF
(2004)]. There was little emphasis placed on creating an environment for innovation
or more importantly recognizing the role of users and their use of technology in the
innovation process.
With the development of the NHS Institute for Innovation in 2005, there is scope
for a co-ordinated approach to the innovation of hard and soft health technologies.
There is however, some doubt about how such an innovation process should be
structured. While models of technology transfer have been adopted from other sec-
tors e.g. the university sector, it remains to be seen that they provide a complete
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and holistic model of technological innovation appropriate to the NHS. The nature
of the NHS makes it very distinct from other sectors, especially with respect to
the range of cultures that exist within the organization. Any set of processes that
support innovation in the NHS must therefore take account of the cultural context
the NHS presents.
3. Technology Transfer Oﬃces in the Public Sector
The focus of technology transfer studies and public policy up to 1980 was on tech-
nology transfer between countries [Reddy and Zhao (1990)]. The economic beneﬁts
of a nation’s internal technology transfer from public sector bodies, has since in the
1980s, become a focus for technology policy. In the US, this shift has been seen
through change to the basis on which public institutions own IP they produce. For
example, the Bahr-Dohl Act 1980 has been cited as triggering an increase in the rate
of patenting by US universities [Nelson (2001)]. Bozeman suggests that this is due
to a change in economic perspective; from an assumption that a free market will be
adequate to facilitate the transfer of technology, to one that recognizes that markets
are not the most eﬃcient mechanisms for innovation and economic growth [Boze-
man (2000)]. It is now recognized that public sector R&D, especially in developing
pre-competitive technology, can be an important complement to R&D carried out
in the private sector. It is however not simply a choice between state run planned
R&D and market led R&D; instead a path between the two is necessary [Lundvall
(1999)]. The position taken in many nations and regions is that the role of public
sector R&D is an important component of a regional or national innovation system
e.g. Japan [Fujisue (1998)], UK [DTI (2004)].
While there is a range of diﬀerent publicly funded research institutions, univer-
sities have been the focus of many technology transfer initiatives in Europe and the
US. One of these initiatives has been the setting up of technology transfer oﬃces
within universities. The purpose of these oﬃces is to act as an intermediary organi-
zation between the private sector and academia. The oﬃces aim to commercialize
a university’s IP. The general commercialization process has been summarized as:
“(a) evaluate and valuate disclosures of new discoveries; (b) seek legal protection
for the technology, primarily through patenting; (c) sell licensing agreements to
industry; and (d) collect royalty, oversee, and enforce contractual agreements with
licensees” [Markman et al. (2005)]. UTTOs are also involved in new venture cre-
ation, such as creation of start-up companies.
Three archetypal structures have been suggested for the form taken by a UTTO.
In a US study [Markman et al. (2005)] over half UTTOs were based within the
formal structure of the university; a large minority were set up as non-proﬁt research
foundations; and a small number (< 10%) were set up as for proﬁt private ventures.
The advantage of the UTTO being placed within the university is simplicity of
management and higher level of control can be exerted by the university over its
activity. In contrast the for-proﬁt private venture limits the level of risk and liability
by the associated university, while allowing greater autonomy. The results of the
diﬀering structures also make university based UTTO more likely to engage in
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licensing for cash/revenues, while the for proﬁt venture based UTTO is more able
to aggressively create business start-ups. A key factor in the success of a UTTO
seems to be that it is decentralised and responsibilities are placed close to research
groups and individuals [Bercovitz et al. (2001)]. A reason for decentralization has
also been cited as the need to provide a buﬀer against the potential conﬂict of
interest between teaching and research within a university [Debackere and Veugelers
(2005)].
4. Technological Innovation in the Healthcare Sector
NHS staﬀ, in common with staﬀ working in all types of organization, have novel
ideas about new technologies and how they should be used. These ideas range from
small “work arounds” conceived to solve an everyday problem; to a major new
medical technology, that has a signiﬁcant impact on how patients are cared for.
These ideas constitute inventions that through a process of innovation become use-
able technologies. The number and range of inventions produced within the NHS
itself is signiﬁcant. Recent innovation competitions within the NHS attract hun-
dreds of entries each year, many of which have commercial value [NHS Innovations
(2004)]. For some inventions their value is only to a localized group of staﬀ. For oth-
ers, the invention can have applicability to the global healthcare market, making
the intellectual property associated with the invention commercially valuable. For
potentially valuable inventions it is important that appropriate commercial pro-
tection of the IP is obtained, so that its commercial value can be fully realized.
This typically involves the ﬁling of a patent. To develop an invention further into
a commercially viable product requires an innovation process that adequately tests
and develops the invention so that it can be produced as a reliable product. In
the case of healthcare technologies this is expensive and time consuming, not least
because of the need to fulﬁll rigorous regulatory requirements. Within Europe there
is now a strong regulatory framework that regulates the medical device industry, for
example the EU Medical Devices Directive (93/42/EC). Two major beneﬁts exist
for the NHS from investing in the technological innovation process. The ﬁrst beneﬁt
of exploiting its IP is the potential income stream from commercial exploitation of
inventions. The second beneﬁt is the potential to transform itself through diﬀusing
innovation within the service, resulting in improvements in eﬃciency, eﬀectiveness
and improved patient care.
Within the NHS a distinction is made between two categories of innovation,
innovative technology and service improvement. This can be seen as a distinc-
tion between “hard technologies” based around physical, technological artifacts e.g.
devices and software; and “soft technologies” based on technological knowledge or
know-how. Within the EU medical devices directive medical technology has been
deﬁned that encompasses mainly hard technologies; thus a hard healthcare technol-
ogy can be seen as an:
. . . instrument, apparatus, appliance, materials or other article,
whether used alone in combination, including the software neces-
sary for its proper application intended by the manufacturer to be
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used for human beings for the purpose of:
• diagnosis, prevention, monitoring, treatment or alleviation of
disease
• diagnosis, monitoring, treatment, or alleviation of or compensa-
tion for an injury or handicap
• investigation, replacement or modification of the anatomy or of
a physiological process
• control of conception
EU Medical Devices Directive (93/42/EC)
In contrast, soft technologies would include knowledge embodied in processes and
procedures used to support patient care e.g. surgical procedures, care plans and
protocols.
The NHS has tended to keep these two categories as separate types of inven-
tion. This is mistaken as for most hard technologies their eﬀective implementation
requires suitable soft technologies. For example in the case of cochlear implants,
implanted devices used to give deaf patients the ability to hear, the hard technology
of the device requires a complex mix of soft technologies to achieve maximum ben-
eﬁt from the implant. These soft technologies deﬁne the wrap around services that
care for the patient before, during and after the implantation of the actual device.
To treat the hard and soft technologies separately ignores their inter-relationships.
For hard healthcare technologies there will inevitably be have a service wrap-around
that embodies softer technologies.
5. Technological Innovation in the NHS
The nature of innovation in any organization is complex. In the case of the NHS
and its hospitals, innovation can take place in many dimensions. This makes it a
particularly complex context for innovation. The source of this complexity is the
range and interrelations of specialist groups and the diversity of services that are
provided. It is suggested that to understand innovation in hospitals it is best to
treat hospitals as “. . . providers of complex services and healthcare system hubs”.
Treating a hospital as a production function; collections of technological and bio-
pharmacological capacities; or information systems leads to a simpliﬁcation of the
complex interrelationships involved [Djellal and Gallouj (2005)]. It would be easy to
see hospital innovation simply in terms of “medical innovation” of hard technologies
including biomedical/bio-pharmacological substances and medical devices; or “soft”
technologies such as care protocols, diagnostic or therapeutic strategies. Similarly,
innovation goes beyond the application of information technologies to healthcare.
Within their own model of hospital innovation, Djellal and Gallouj stress recognizing
innovation of services as the main unit of analysis, rather than a speciﬁc technology.
They suggest that innovation results in the extension, specialization, intensiﬁcation
or recombination of a service’s constituent technologies. These changes to a ser-
vice will result at the component and architectural levels of technology [Henderson
and Clark (1990)]. By maintaining a focus on the service however, a link is main-
tained between the technology and its implemented use in the organization. The
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implication of this is that while it is useful for pharmaceutical companies, medical
device manufacturers and even universities to consider “medical innovations” from
the perspective of speciﬁc hard and soft technologies, to understand innovation in
hospitals it is imperative that a broader view is taken.
6. Does the UTTO Model Fit the Needs of the NHS?
The structure and function of UTTOs has been the target for much research. For
most universities the UTTO draws together a wide range of skills and knowledge
to support a range of processes. These include not just straightforward commercial-
ization but also act as a focus for other university-industry relationships such as a
contract research. It is perhaps because the UTTO encompasses a well developed
and sophisticated range of business models with proven eﬀectiveness, that it is the
predominant model adopted for NHS innovation hubs. The context for technology
transfer in the university sector diﬀers to that in the NHS, is in terms of the aims of
the respective organizations, their structural characteristics and the basis on which
technology transfer performance is evaluated.
6.1. Diﬀerences in the context for technology transfer
The NHS is very distinct from the university sector in terms of its aims and under-
lying structures and culture. While there are links between the two sectors, par-
ticularly in teaching hospitals, it would be wrong to generalize between them.
The functions of the two sectors are very diﬀerent. In universities, the two pri-
ority activities are teaching and research. University teaching emphasises academic
approaches to knowledge, while research spans both curiosity-driven and strategic
applied research. The resulting outputs of universities are therefore educated adults
and published research. While other outputs include patents, the key performance
indicators for universities are numbers of students and number/quality of research
publications. In contrast, for NHS hospitals the main purpose is provision of patient
care. While research takes place within the NHS, it is primarily applied research.
The result of these two diﬀering purposes means that the respective organizations
have distinct diﬀerences in structure and culture. A common structure to both is
that of a professional bureaucracy [Mintzberg (1993)]. However the professional
identities of staﬀ in the two sectors are very diﬀerent. In the university sector, staﬀ
value the academic freedom to carry out both “blue sky” or applied research, though
research funding regimes can constrain this freedom. There is doubt however that
the pursuit of commercially oriented research is consistent with the goal of cre-
ating reputation enhancing academic knowledge [Goldfarb and Henrekson (2003)].
University research can be experimental and is supported by a risk-tolerant envi-
ronment, particularly where staﬀ have tenure. The main motive for research is
development of professional status based on the quality of published work, rather
than ﬁnancial incentives. In contrast, NHS research is predominantly applied and
is carried out in an environment characterized as risk-adverse and highly regulated,
both in terms of scientiﬁc and ethical standards. Innovations created by NHS staﬀ
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are often problem oriented and practice-based innovations, concerned with a speciﬁc
health care service.
6.2. Diﬀerences in the evaluation criteria for technology transfer
While both sectors have been the focus of attempts to increase levels of technology
transfer, the basis on which initiatives are evaluated will diﬀer between the sec-
tors. Bozeman suggests criteria on which technology transfer from universities is
evaluated [Bozeman (2000)].
(1) The “Out the door” criteria is based on simply whether a technology transfer
occurs, this is perhaps the crudest measure of success, though easiest to measure
e.g. number of licenses granted in a year.
(2) Market impact/economic development is more concerned with the eﬀect of a
technology transfer, either on the competitiveness of the recipient organization
or the macro economic impact of the transfer.
(3) Political reward emphasizes the political pay-oﬀ of a particular technology
transfer.
(4) Opportunity cost of technology transfer activities, recognizing that the
resources put into technology transfer activities absorb resources for other
activities.
(5) Technology transfer can result in an increase in scientiﬁc and technical human
capital that increases the university’s research capacity.
Bozeman’s criteria provide a rounded set of criteria for evaluating technology trans-
fer. When reviewing the university sector Bozeman found that only a small number
of criteria were used, usually those for which there were easily established metrics,
for example number of licenses granted. Unfortunately, metrics based only on num-
bers of patents or licenses fail to reﬂect the true complexity of technology transfer.
The establishment of a patent or license does not always unequivocally signal a suc-
cessful technology transfer. In addition for “non-embryonic inventions” requiring
little additional development, protection of IPR is only important with respect to
allowing universities to collect revenues, rather than actually facilitating technology
transfer [Colyvas et al. (2002)]. For policy makers there needs to be a distinction
between processes that facilitate the generation of income from technology trans-
fer; and those that facilitate technology transfer. While the UTTO can play an
important part in supporting income generation, through the commercialization of
inventions, it is unclear whether the wider beneﬁts alluded to by Bozeman’s criteria
are supported by UTTOs.
6.3. The NHS as a complex technology transfer problem
UTTOs have played an important function in commercializing a large number and
range of IP from the university sector. In speciﬁc areas such as biotechnology their
function has gone beyond just providing services required to gain protection of IP,
to strategic decision-making on how best to commercialize an idea by developing
industry relationships and even triggering the creation of start-up companies. Exist-
ing links between the university sector and the NHS, focused in medical schools,
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has meant that some UTTOs already serve both university and NHS organizations.
A natural step in encouraging better management of IP in the NHS is to widen
access to TTO services for NHS staﬀ. There are three factors that complicate the
issue of promoting technology transfer in the NHS.
(1) In the healthcare area UTTO have tended to focus on hard technologies. These
technologies are more amenable to protection such as patents, than the wider
procedures or processes within which they are used. So for an innovative surgical
procedure, the only practical way of protecting the associated IPR, is to patent
devices used in the procedure.
(2) The nature of UTTO commercialization processes leads to a separation between
the hard and soft technologies supporting its use. Thus, a tight boundary is
maintained between the technology and the context of its use, e.g. a service
delivery process. This is particularly the case in universities (with the exception
of medical schools), where R&D is likely to be carried out remotely from the
ﬁnal context of use.
(3) Evaluation of UTTO is commonly based on metrics concerned with eﬃciency
of technology transfer, e.g. number of patents, licenses, start-ups. This can
be appropriate in a university where emphasis is on increased quantities of
technology transfer and maximizing resulting revenues. In the NHS however,
eﬀective technology transfer, and in particular the beneﬁts gained through dif-
fusion of NHS innovations within the service, are major concerns. While not
providing major new revenue streams for the NHS, this internal technology
transfer has the potential for improvements both in eﬃciency and eﬀectiveness.
Ultimately, improved patient care within the service can result from internal
technology transfer. Evaluation of technology transfer activities must encom-
pass both eﬀective commercialization and enhanced patient care. Several of
Bozeman’s evaluation criteria have particular relevance to the NHS and sug-
gest that any innovation management should value outcomes such as capacity
building equally with improved income streams.
7. Cultural Context for NHS Innovation
Many organizations that are seen as innovative have been described as having
a culture that is conducive to innovation. Many large organizations such as 3M,
Microsoft and Hewlett Packard have their innovative cultures linked to charismatic
and innovative leaders. These leaders have inﬂuenced values and practises support-
ing innovation over a long period [Deschamps (2003)]. The presence of an innovation
culture can be a pre-requisite to encouraging technological innovation in the NHS.
This raises the question of whether the NHS does have an innovative culture. An
attempt at characterizing the culture of the NHS is prone to generalizations sim-
ply because of the size and diversity of the organization. Several observations can
however be made.
The NHS is organized into strong functional specialisms, which are overlaid
with strong professional roles. In turn these functions and roles have become
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institutionalized into a tight bureaucratic structure that supports and co-ordinates
its activities.
The primary base of power in the NHS has been medical knowledge and as such
doctors in particular hold signiﬁcant power [Worthington (2004)]. Other healthcare
professionals such as nurses and paramedics hold lower levels of power and inﬂuence.
The powerful position of doctors also leads to the organization having a predom-
inantly positivist world view. This leads to scientiﬁc method being the primary
process for validating knowledge. This has implications for technological innovation
as evaluation of technology tends to be based on a search for “scientiﬁc fact”. This
can be limiting as epistemologies based in the social sciences carry less credence
[Jones (2001)]. Thus despite the need to recognize the socio-technical dimension of
technology, NHS decision-making underpinned by a knowledge validation process
based on a positivist epistemology. Though alternative epistemologies have been
used in clinical settings [Reason and Bradbury (2000)], they remain marginal. This
strong positivist worldview is illustrated by a statement from a senior manager
at the NHS Modernisation Agency when commenting on continuous improvement
methodology applied to the NHS. They stated that “. . . data are presented in a
format that is easily understood and statistically valid, which appeals to doctors. . . ”
[author’s emphasis] [Rogers et al. (2004)]. It is revealing from this statement that in
order to drive improvements to organizational rather than medical operations, NHS
decision making requires scientiﬁc levels of proof. As increasingly recognized in the
management literature this can lead to a myopia in which only the measurable is
managed, or even believed.
The cultural propensity for scientiﬁc knowledge leads to initiatives being led by
scientiﬁc method. For example, the NHS has since the early 1990s placed emphasis
on “evidence based clinical practice”. This approach to clinical practice is concerned
that where research data is available it should drive clinical practice. There have also
been moves to develop “evidence based policy” in the NHS. Both these initiatives
are an attempt to transfer scientiﬁcally validated knowledge into clinical practice
and policy making. There has been some criticism of evidence based policy on the
grounds that research results are often too context speciﬁc to be widely generalized
[Black (2001)]. Evidence based policy in the NHS has attracted speciﬁc criticism
on the grounds that policy requires a more pluralist and diverse approach and to
recognize that policy often requires compromises between competing view-points
[Marmot (2004)]. Evidence based initiatives are an example of the predominantly
positivist culture in the NHS rooted in the dominant views of the medical profession.
While emphasis on scientiﬁc knowledge and the division of the organization on
functional specialisms has allowed the enhancement of patient care through prac-
titioners gaining specialist skills; innovation has been impeded by rigidity; peck-
ing orders; strict demarcation; tribalisism between staﬀ; and departmental silos
[Rushmer et al. (2004)]. While the source of many innovations are based in the
novel combination of diverse disciplines; the NHSs predominantly functionally based
structure acts against such innovation.
The NHS has a strong culture of professional autonomy because of the NHS’s
structure primarily being based on functional specialisms [Worthington (2004)].
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This should provide an eﬀective setting for innovation work to occur, as professional
staﬀ have some control and discretion in how they approach their work. There are
however a number of factors that stop individuals pursuing certain innovations.
There is increasing requirement for new practices to be rigorously tested prior to
being approved by regulatory authorities at national and regional levels. This in
itself carries with it a signiﬁcant overhead that can potentially retard innovative
activities. The role of NHS staﬀ is primarily to deliver services to patients. The
demand for such services is high and so for many staﬀ there is little time to spend
on innovative activities.
Since the 1980s there has been a gradual change in the role of professional man-
agers in the NHS. Up to the 1980s the role of managers has been characterized as
to support the work of professionals and nurses in carrying out their work. Their
primary role was seen as ensuring that the necessary resources were available at
the appropriate time [Worthington (2004)]. Only after the Griﬃths inquiry of 1983
was the role of managers made more explicitly concerned with performance man-
agement or strategic change. This has led to a conﬂict between the work of clinical
professionals and management.
In order to develop a thriving innovation context in the NHS, account needs
to be taken of its culture. As outlined above however this is not simple as the
NHS’s culture is complex and heterogeneous; complex because of the web of power
relationships; heterogeneous because of the diversity of disciplines and roles. In
addition to its size the NHS also experiences a high rate of change. Signiﬁcant
change has been rooted in external pressures e.g. government initiatives. Perhaps
the most acute driver of change is technology. The rate of technological change has
implications for the organization in terms of both resourcing new technology and
the development of skills to use it. The past twenty years has seen a succession of
initiatives in the NHS, this has resulted in “change fatigue” becoming endemic in
staﬀ. For these reasons an approach to managing innovation in the NHS must be
sensitive to the diverse cultures and recognize that for an organization experiencing
rapid change any “solutions” are likely to be only transitory.
8. A Research Agenda
A number of potentially rich areas of research are raised by the recent initiatives
aimed at generating and improving the management of innovation in the NHS. At
a general level, an assessment of the approaches taken to innovation management,
and their levels of success, is valuable in providing insights into how future initia-
tives are designed. The sheer size of the NHS as the largest healthcare provider
in the world means that this has an intrinsic value in its potential to support
continuous improvement and innovation. The insights gained can however be also
relevant to other large, public-sector organizations. Operationally focused, yet tech-
nically dependent, public service organizations can beneﬁt from understanding the
problem of innovation management. Such sectors include: policing, education and
social-care.
July 7, 2006 20:33 WSPC/ws-ijitm 00074
Model of Technology Transfer for Public Sector Healthcare Services 183
Table 1. Distinction between innovation in Universities/PSREs and NHS Organizations.
University/PSRE NHS Organization
Context Research and invention is
primary purpose
Operational focus with
invention a byproduct of
practice
Development of published work
improves professional status
Innovation is problem oriented
Highly regulated and risk averse
Experimental and risk tolerant
Evaluation criteria for
innovation
Quantity of patents and licenses
Improved technical human
capital
Prestige and reputation
Improved operational eﬃciency
Improved quality of care
Value of income stream from
technology licenses Political
kudos
Technology Hard technologies Closely coupled hard and soft
technologies
Proximity of R&D eﬀort
to context of use
Distant
Multidisciplinary teams drawn
from specialist research staﬀ
Close to the context of use
Operationally focused
individuals and teams
Mechanisms for diﬀusion
and adoption of
technology
Market mechanisms Diﬀusion of soft technology
This paper has suggested that treating the NHS as simply another PSRE,
without recognizing its unique characteristics and distinct diﬀerences from uni-
versities and research institutes (see Table 1), can lead to the application of a
sub-optimal model of innovation management. For example, the un-critical appli-
cation of a UTTO model, could undermine the development of a systemic approach
to innovation management. A systemic model of innovation would allow the value
of inventions to be assessed using multiple criteria, not just their potential as an
income stream from commercial exploitation. Additional criteria are required to
take into account the potential for internal eﬃciency and patient care improve-
ment beneﬁts. Such criteria would have to be sensitive to the synergies developed
between hard and soft technologies. In addition, the incentives and disincentives
for NHS staﬀ engaging in innovative activities needs to be clearly understood
and addressed. Finally, the diverse range of formal and informal innovation activ-
ities in the NHS requires a contingent approach to innovation process design;
better understanding of the variables aﬀecting the design of these processes is
needed.
Further research would be beneﬁcial to establish insights into eﬀective innovation
in the NHS. This suggests a research agenda based around ﬁve issues.
(1) The problem identiﬁed by government is not that innovation fails to occur in
the NHS but that exploitation of inventions is not always as eﬀective as it could
be. This leads to a need to examine what actual innovation processes operate
in the NHS. Research in this area has the potential to diﬀerentiate between the
oﬃcially recognized and articulated innovation practices and those that occur
on an informal and unoﬃcial basis. A comparison of the oﬃcial and un-oﬃcial
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innovation processes has potential to strengthen new initiatives by taking into
account those informal processes that potentially support or retard innovation.
(2) The heterogeneity of NHS inventions suggests that a contingent approach to
their innovation process is required. Further research has the potential to iden-
tify those contingent variables that inﬂuence the design of the innovation process
applied to a speciﬁc invention.
(3) The implied model of innovation embodied in UTTO models is one of technol-
ogy push. While the initiatives to manage NHS innovation have improvement
of patient care as a primary objective, the emphasis on technology push results
in the main objective becoming development of commercially successful health-
care products. It is possible that the development of commercially successful
healthcare products beneﬁts patient care, through making new technologies
more widely available via market mechanisms. The involvement of the private
sector in the development process can ensure that the technology developed sat-
isﬁes regulatory requirements and also make products available at lower price
due to competition in the global healthcare market. By establishing a product
in the global market place, its diﬀusion and use back into the NHS can occur
more readily. For many technologies this mechanism can be eﬀective, on the
basis of gaining royalties for the NHS and acting as an eﬀective mechanism
for technology diﬀusion. The assumption however that all inventions should
have commercial viability in order to merit development through the innova-
tion pipeline is ﬂawed. Unfortunately tests for commercial viability carried out
as part of a technology assessment must be based purely on forecast of poten-
tial income generated from the commercial product. This emphasis hides other
potential beneﬁts of an invention, such as improvements in eﬀectiveness, quality
of patient care or enabling better internal processes within the NHS. Research
is needed to consider how assessment of inventions is best structured where
the primary target of an invention is the NHSs internal market for technology
rather than the global healthcare market. This is particularly the case where the
advantages of the technology are based on synergy between a hard technology
and a service wrapping provided by the NHS.
(4) The inventions produced within the NHS are rooted in a practice-based rather
than a research-based culture. Further research is needed to examine how the
innovation process must diﬀer from that applied in PRSEs, including univer-
sities. A key factor to consider is the extent to which an invention is coupled
to its original context. Within the NHS there will be cases where technologies
that were invented to support speciﬁc procedures or ways or working, will be
diﬃcult to separate into distinct products. The tight coupling with organiza-
tional practices can be the crucial linkage in making a new technology usable
and eﬀective. For the NHS this implies that the innovation process must mange
not just hard technologies but also any “service wrapping” that supports its
eﬀective use.
(5) The ﬁnal area of research that the paper leads to is how the model of innovation
management adopted in the NHS ﬁts with its culture. As noted in the paper the
shared values and attitudes of NHS staﬀ are based around the organization’s
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purpose to deliver patient care. This is distinct from values held by staﬀ in
other PSREs, where the predominant values support a research focused culture.
The implication of this is that models of innovation management taken from
other sectors such as universities are incommensurate with the values of NHS
staﬀ. Technology transfer initiatives in particular that emphasise transfer out to
commercial markets, can sit uncomfortably with the NHS, especially where the
major market is within the NHS itself. This raises questions about whether the
conventional process used for “protecting” IP, through secrecy and/or patenting
are actually counter-productive to technology diﬀusion within the service.
Further research is planned that will build case studies of the actual processes
followed by NHS staﬀ in pursuing successful innovation. It is intended that these
will provide insights into the contingent variables aﬀecting design of the innovation
processes including: the co-development of soft and hard technologies; the role of
NHS staﬀ as both innovators and users; and the impact of the values and beliefs
about technology that shape innovation processes.
References
Baker, J. (1999). Creating Knowledge Creating Wealth: Realising the Economic Potential
of Public Sector Research Establishments. A report by John Baker to the Minister for
Science and the Financial Secretary to the Treasury. HM Treasury. London, UK.
Bercovitz, J., Feldman, M. et al. (2001). Organizational structure as a determinant of
academic patent and licensing behavior: An exploratory study of Duke, Johns Hopkins,
and Pennsylvania State Universities. The Journal of Technology Transfer, 26, 1–2:
21–35.
Black, N. (2001). Evidence based policy: Proceed with care. British Medical Journal, 323,
7307: 275–278.
Bozeman, B. (2000). Technology transfer and public policy: A review of research and
theory. Research Policy, 29, 4–5: 627–655.
Colyvas, J. and Crow, M. et al. (2002). How do university inventions get into practice?
Management Science, 48, 1: 61–72.
Culyer, A. (1994). Supporting Research and Development in the NHS. A report to the
minister for health by a research and development task force chaired by Professor
Anthony Culyer. HMSO. London, UK.
Debackere, K. and Veugelers, R. (2005). The role of academic technology transfer organi-
zations in improving industry science links. Research Policy, 34, 3: 321–342.
Deschamps, J. P. (2003). Innovation and Leadership. The International Handbook on Inno-
vation. L. V. Shavinina. Amsterdam. Boston, Elsevier Science, xxviii: 1171.
Djellal, F. and Gallouj, F. (2005). Mapping innovation dynamics in hospitals. Research
Policy, 34, 6: 817–835.
DoH (2002). The NHS as an Innovative Organisation, a Framework and Guidance on
the Management of Intellectual Property. Department of Health. Report No. 29030.
London, UK.
DTI (2004). Knowledge Transfer and Public Sector Research Establishments (PSREs).
Department of Trade and Industry. London, UK.
Etzkowitz, H. and Leydesdorﬀ, L. (2000). The dynamics of innovation: From National
Systems and “Mode 2” to a Triple Helix of university-industry-government relations.
Research Policy, 29, 2: 109–123.
July 7, 2006 20:33 WSPC/ws-ijitm 00074
186 C. Savory
Fujisue, K. (1998). Promotion of academia-industry cooperation in Japan — Establish-
ing the “law of promoting technology transfer from university to industry” in Japan.
Technovation, 18, 6–7: 371–381.
Goldfarb, B. and Henrekson, M. (2003). Bottom-up versus top-down policies towards the
commercialization of university intellectual property. Research Policy, 32, 4: 639–658.
Henderson, R. M. and Clark, K. B. (1990). Architectural innovation: The reconﬁguration
of existing product technologies. Administrative Science Quarterly, Administrative Sci-
ence Quarterly, 35: 9.
HITF (2004). Better Health Through Partnership: A Programme for Action. Health Indus-
tries Task Force, Department of Health, Report No. 265090. London, UK.
Howells, J. (1997). Rethinking the market-technology relationship for innovation. Research
Policy, 25, 8: 1209–1219.
Jones, M. (2001). An interpretive method for the formative evaluation of an electronic
patient record system. 8th European Conference on IT Evaluation, Oriel College,
Oxford, UK, MCIL.
Lundvall, B.-A. (1999). Technology policy in the learning economy. Innovation Policy
in a Global Economy. D. Archibugi, J. Howells and J. Michie, Cambridge, England,
New York, Cambridge University Press, pp. 19–34.
Markman, G. D., Phan, P. H. et al. (2005). Entrepreneurship and university-based tech-
nology transfer. Journal of Business Venturing, 20, 2: 241–263.
Marmot, M. G. (2004). Evidence based policy or policy based evidence? British Medical
Journal, 328, 7445: 906–907.
Mintzberg, H. (1993). Structure in Fives: Designing Eﬀective Organizations, Englewood
Cliﬀs; London, Prentice Hall, Prentice-Hall International.
Nelson, R. R. (1990). Capitalism as an engine of progress. Research Policy, 19, 3: 193–214.
Nelson, R. R. (2001). Observations on the Post-Bayh-Dole rise of patenting at American
Universities. The Journal of Technology Transfer, 26, 1–2: 13–19.
NHS Innovations (2004). NHS Innovations Annual Report 2003/2004. NHS Innovations.
London, UK.
Oﬃce of Science and Technology (2000). The Government Response to the Baker Report:
Creating Knowledge, Creating Wealth: Realising the Economic Potential of Public Sec-
tor Research Establishments. HM Treasury. London, UK.
Reason, P. and Bradbury, H. (eds.) (2000). Handbook of Action Research: Participative
Inquiry and Practice, Sage.
Reddy, N. M. and Zhao, L. M. (1990). International technology-transfer — A review.
Research Policy, 19, 4: 285–307.
Rogers, H., Silvestor, K. et al. (2004). NHS Modernisation Agency’s way to improve health
care. British Medical Journal, 328: 463.
Rushmer, R., Kelly, D. et al. (2004). Introducing the learning practice — I. The charac-
teristics of learning organizations in primary care. Journal of Evaluation in Clinical
Practice, 10, 3: 375–386.
Siegel, D. S., Waldman, D. et al. (2003). Assessing the impact of organizational practices
on the relative productivity of university technology transfer oﬃces: An exploratory
study. Research Policy, 32, 1: 27–48.
UK Government (2000). The NHS Plan, A Plan for Investment, a Plan for Reform, HMSO.
London.
Worthington, F. (2004). Management, change and culture in the NHS: Rhetoric and reality.
Clinician in Management, 12, 2: 55–67.
July 7, 2006 20:33 WSPC/ws-ijitm 00074
Model of Technology Transfer for Public Sector Healthcare Services 187
Biography
Clive Savory is a lecturer in technology management at the Open University, UK.
He has an MSc in Information Systems from City University, UK, and has indus-
trial experience in both the manufacturing and software industries. He now teaches
technology management at postgraduate level, specializing in technology strategy,
organizational learning, knowledge management and innovation. He is currently
researching the management of innovation within the UK’s National Health Ser-
vice. This work focusses on the ways that practice-based innovation can be best
facilitated.
